Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.42 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780304 | 0.79 | CYP3A4 (0.54) | LSSITGB3ITGA2BF10CYP3A4 | |
| SCHEMBL3430323 | 0.79 | MAPT (0.38) | CYP3A4KDM4EABL1LMNA | |
| SCHEMBL14949547 | 0.79 | MAPT (0.38) | CYP3A4KDM4EABL1LMNA | |
| SCHEMBL6370587 | 0.79 | LSS (0.46) | LSSITGB3ITGA2BF10CYP3A4 | |
| SCHEMBL4721762 | 0.75 | LSS (0.54) | LSSITGB3ITGA2BF10 | |
| SCHEMBL4721161 | 0.75 | LSS (0.54) | LSSITGB3ITGA2BF10 | |
| SCHEMBL6370590 | 0.73 | LSS (0.46) | LSSITGB3ITGA2BF10 | |
| SCHEMBL742952 | 0.72 | ITGB3 (0.60) | LSSITGB3ITGA2BKDM4ELMNA | |
| SCHEMBL16887557 | 0.70 | CYP2C9 (0.53) | LSSITGB3ITGA2BF10CYP3A4 | |
| Hydrochloric Acid SCHEMBL3319271 | 0.70 | ITGB3 (0.59) | LSSITGB3ITGA2BKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684744-A4 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-17 | — | — | EP | claimed |
| EP-1684744-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | claimed |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | claimed |
| WO-2005032472-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| EP-1684744-A4 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1684744-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | disclosed |
| WO-2005032472-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | PEPD, SERPINE1, PRSS1 | LSS 2166/4885ITGB3 4003/4885ITGA2B 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.